190 related articles for article (PubMed ID: 30395904)
1. Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial.
Sio TT; Atherton PJ; Pederson LD; Zhen WK; Mutter RW; Garces YI; Ma DJ; Leenstra JL; Rwigema JM; Dakhil S; Bearden JD; van der Veen SJ; Ganti AK; Schild SE; Miller RC
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):686-696. PubMed ID: 30395904
[TBL] [Abstract][Full Text] [Related]
2. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
Kharofa J; Cohen EP; Tomic R; Xiang Q; Gore E
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):238-43. PubMed ID: 22300564
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
Antonadou D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
[TBL] [Abstract][Full Text] [Related]
4. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial.
Wang XS; Shi Q; Mendoza T; Lin S; Chang JY; Bokhari RH; Lin HK; Garcia-Gonzalez A; Kamal M; Cleeland CS; Liao Z
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):100-107. PubMed ID: 31627177
[TBL] [Abstract][Full Text] [Related]
5. Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database.
Wang H; Liao Z; Zhuang Y; Xu T; Nguyen QN; Levy LB; O'Reilly M; Gold KA; Gomez DR
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1071-7. PubMed ID: 24161424
[TBL] [Abstract][Full Text] [Related]
6. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic ACE-Inhibition Mitigates Radiation-Induced Pneumonitis by Suppressing ACE-Expressing Lung Myeloid Cells.
Sharma GP; Fish BL; Frei AC; Narayanan J; Gasperetti T; Scholler D; Pierce L; Szalewski N; Blue N; Medhora M; Himburg HA
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):177-191. PubMed ID: 35093482
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study.
Yue J; Shi Q; Xu T; Jeter M; Chen TY; Komaki R; Gomez DR; Pan T; Cleeland CS; Liao Z; Wang XS
Qual Life Res; 2018 Jun; 27(6):1563-1570. PubMed ID: 29549533
[TBL] [Abstract][Full Text] [Related]
9. Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123.
Small W; James JL; Moore TD; Fintel DJ; Lutz ST; Movsas B; Suntharalingam M; Garces YI; Ivker R; Moulder J; Pugh S; Berk LB
Am J Clin Oncol; 2018 Apr; 41(4):396-401. PubMed ID: 27100959
[TBL] [Abstract][Full Text] [Related]
10. Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial.
Hoover DA; Capaldi DP; Sheikh K; Palma DA; Rodrigues GB; Dar AR; Yu E; Dingle B; Landis M; Kocha W; Sanatani M; Vincent M; Younus J; Kuruvilla S; Gaede S; Parraga G; Yaremko BP
BMC Cancer; 2014 Dec; 14():934. PubMed ID: 25496482
[TBL] [Abstract][Full Text] [Related]
11. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial.
Sio TT; Blanchard MJ; Novotny PJ; Patel SH; Rwigema JM; Pederson LD; McGee LA; Gamez ME; Seeger GR; Martenson JA; Grover Y; Neben Wittich MA; Garces YI; Foote RL; Miller RC; Halyard MY
Mayo Clin Proc; 2019 Sep; 94(9):1814-1824. PubMed ID: 31405750
[TBL] [Abstract][Full Text] [Related]
13. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
14. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
[TBL] [Abstract][Full Text] [Related]
15. Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors.
Paster RZ; Snavely DB; Sweet AR; Draper RA; Goldberg AI; Soffer BA; Sweet CS
Clin Ther; 1998; 20(5):978-89. PubMed ID: 9829449
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
Baker JV; Huppler Hullsiek K; Prosser R; Duprez D; Grimm R; Tracy RP; Rhame F; Henry K; Neaton JD
PLoS One; 2012; 7(10):e46894. PubMed ID: 23082133
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
Dandekar VK; Young J; Kiel K; Bonomi P; Fidler MJ; Batus M; Sher DJ
Am J Clin Oncol; 2015 Dec; 38(6):605-9. PubMed ID: 24781341
[TBL] [Abstract][Full Text] [Related]
19. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
20. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial.
Wynn RB; Mehta V
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S99-104. PubMed ID: 16015543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
